Dr. Neelapu on Updated ZUMA-1 Findings in Non-Hodgkin Lymphoma

Sattva Neelapu, MD
Published: Monday, Dec 11, 2017



Sattva Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the updated findings of the ZUMA-1 trial investigating axicabtagene ciloleucel (axi-cel; Yescarta) for patients with refractory aggressive non-Hodgkin lymphoma.

ZUMA-1 is a phase II multicenter trial of axicabtagene. which is a CD19-targeted chimeric antigen receptor (CAR) T-cell therapy, which enrolled 108 patients with refractory aggressive NHL, Neelapu explains. Eligible patients had no response to their last line or therapy, or they experienced relapse within 12 months after autologous stem cell transplant.

Results presented at the 2017 ASH Annual Meeting include a median follow-up of 15.4 months, with the best ORR of 82% and a best complete remission (CR) rate of 58%. Additionally, 40% patients remain in CR; in the ongoing cohort at 15.4 months, the ORR was 42%. The median overall survival and the median duration of response for the CR patients have not been reached. Currently, 56% of patients remain alive, he concludes.


Sattva Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the updated findings of the ZUMA-1 trial investigating axicabtagene ciloleucel (axi-cel; Yescarta) for patients with refractory aggressive non-Hodgkin lymphoma.

ZUMA-1 is a phase II multicenter trial of axicabtagene. which is a CD19-targeted chimeric antigen receptor (CAR) T-cell therapy, which enrolled 108 patients with refractory aggressive NHL, Neelapu explains. Eligible patients had no response to their last line or therapy, or they experienced relapse within 12 months after autologous stem cell transplant.

Results presented at the 2017 ASH Annual Meeting include a median follow-up of 15.4 months, with the best ORR of 82% and a best complete remission (CR) rate of 58%. Additionally, 40% patients remain in CR; in the ongoing cohort at 15.4 months, the ORR was 42%. The median overall survival and the median duration of response for the CR patients have not been reached. Currently, 56% of patients remain alive, he concludes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x